Published in Drugs on January 01, 1990
Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol (1981) 4.75
GLOMERULONEPHRITIS. A SURVEY OF THE FUNCTIONAL ORGANIZATION OF THE KIDNEY IN VARIOUS STAGES OF DIFFUSE GLOMERULONEPHRITIS. J Clin Invest (1944) 4.04
Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet (1983) 3.01
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest (1985) 2.99
Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed) (1982) 2.99
Renal function in renal diseases. Am J Med (1950) 2.96
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest (1986) 2.91
Nephron adaptation to renal injury or ablation. Am J Physiol (1985) 2.65
Effects of dietary protein and phosphorus restriction on the progression of early renal failure. Kidney Int (1982) 1.83
Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med (1985) 1.81
Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int (1976) 1.77
Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. Am J Cardiol (1982) 1.77
Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int (1983) 1.65
Long-term follow-up of patients who underwent unilateral nephrectomy in childhood. Lancet (1985) 1.55
Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Intern Med (1989) 1.53
Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet (1984) 1.53
Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int (1987) 1.25
Hypertension and proteinuria: long-term sequelae of uninephrectomy in humans. Kidney Int (1984) 1.22
Dietary protein restriction in established renal injury in the rat. Selective role of glomerular capillary pressure in progressive glomerular dysfunction. J Clin Invest (1986) 1.21
Role of heparin as a protective agent following reduction of renal mass. Kidney Int (1984) 1.20
Clinical experience with captopril in the treatment of severe drug-resistant hypertension. Am J Cardiol (1982) 1.17
Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest (1988) 1.17
Focal segmental glomerulosclerosis and progressive renal failure associated with a unilateral kidney. Pediatrics (1984) 1.15
Focal and segmental glomerulosclerosis and porteinuria associated with unilateral renal agenesis. Lab Invest (1982) 1.14
The effect of a keto acid-amino acid supplement to a restricted diet on the progression of chronic renal failure. N Engl J Med (1984) 1.14
The modification of diet in renal disease study. N Engl J Med (1989) 1.13
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res (1988) 1.13
Serial micropuncture analysis of single nephron function in subtotal renal ablation. Kidney Int (1988) 1.11
Captopril in hypertension; seven years later. J Cardiovasc Pharmacol (1985) 1.10
Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model. Am J Med (1985) 1.08
Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int (1987) 1.04
Renal function before and after unilateral nephrectomy in renal donors. Kidney Int (1975) 1.03
Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med (1985) 0.96
Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron (1984) 0.95
Progression of renal failure in patients with renal disease of diverse etiology on protein-restricted diet. Kidney Int (1985) 0.95
Impact of renal donation. Long-term clinical and biochemical follow-up of living donors in a single center. Am J Med (1985) 0.94
Functional response of healthy and diseased glomeruli to a large, protein-rich meal. J Clin Invest (1988) 0.94
Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med (1986) 0.91
Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations. Am J Med (1988) 0.91
Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med (1985) 0.90
N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest (1988) 0.90
Effect of heparin on the glomerular structure and function of remnant nephrons. Kidney Int (1988) 0.89
Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis (1989) 0.88
Antiproteinuric effect of captopril in primary glomerular disease. Nephron (1987) 0.88
Preventing the progression of human renal disease: have rational therapeutic principles emerged? Kidney Int (1988) 0.88
Reduction of blood pressure retards the progression of chronic renal failure in man. Nephrol Dial Transplant (1988) 0.86
Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol (1986) 0.86
Progressive glomerular injury after limited renal infarction in the rat. Am J Physiol (1988) 0.85
Low-protein diet supplemented by keto acids in chronic renal failure: a prospective controlled study. Kidney Int Suppl (1983) 0.85
Captopril slows the progression of chronic renal disease in partially nephrectomized rats. Toxicol Appl Pharmacol (1985) 0.82
Focal glomerulosclerosis and proteinuria in patients with solitary kidneys. Arch Intern Med (1986) 0.82
Progressive renal failure in a remnant kidney. Br Med J (Clin Res Ed) (1985) 0.81
Effects of preglomerular and postglomerular vascular resistance alterations on filtration fraction. Kidney Int Suppl (1987) 0.81
Hyperperfusion injury of the human kidney in different glomerular diseases. Am J Nephrol (1988) 0.79
Early dietary protein restriction protects the failing kidney. Kidney Int Suppl (1985) 0.78
The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens (1988) 0.77
Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med (1988) 0.77
Long-term effect of captopril on kidney function in various forms of hypertension. Klin Wochenschr (1984) 0.76
Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency. Arch Intern Med (1988) 0.76
Role of hypertension on the progression of renal disease in man. Blood Purif (1988) 0.76
Renal haemodynamics and comparative effects of captopril in patients with benign- or malignant-essential hypertension, or with chronic renal failure. Clin Exp Hypertens A (1987) 0.76
Functional patterns in renal disease. Ann Intern Med (1948) 0.76
Twenty years of hyperfiltration without diabetic-type glomerulosclerosis. Am J Kidney Dis (1989) 0.76
Captopril in the treatment of hypertension in predialytic end-stage renal disease. Contrib Nephrol (1984) 0.76
Long term therapy by captopril in children with renal hypertension. Clin Exp Hypertens A (1986) 0.76
Progressive renal disease: is the slippery slope species specific? J Lab Clin Med (1987) 0.76
Proteinuria and renal function in kidney transplant donors 10-18 years after donor uninephrectomy. Ups J Med Sci (1985) 0.76
Effect of captopril on renal hemodynamics in the treatment of resistant renal hypertension. Hypertension (1983) 0.76
Antihypertensive efficacy of enalapril maleate on impaired renal function. Kidney Int Suppl (1988) 0.76
Preservation of renal structure and function in the rat remnant kidney model of chronic renal failure by enalapril treatment. Pathology (1987) 0.75
Effects of angiotensin II and of angiotensin converting enzyme inhibition in chronic renal failure. Kidney Int Suppl (1987) 0.75
Long term effect of captopril in hypertension with chronic renal failure. Proc Eur Dial Transplant Assoc (1980) 0.75
Captopril for refractory hypertension in patients with impaired renal function. J R Soc Med (1985) 0.75
Preservation of kidney function by use of converting-enzyme inhibitors for control of hypertension. Lancet (1987) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis (1999) 2.38
Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother (1984) 2.09
The glomerular mesangium. Kidney Int (1980) 1.83
Experimental pyelonephritis. XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis. Yale J Biol Med (1967) 1.67
Mechanism of Escherichia coli alpha-hemolysin-induced injury to isolated renal tubular cells. Am J Pathol (1987) 1.57
Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med (1993) 1.54
Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med (1994) 1.44
Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int (1991) 1.42
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine (2001) 1.41
Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids. J Clin Microbiol (1984) 1.36
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst (2000) 1.35
Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis (1983) 1.35
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther (1985) 1.34
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet (1996) 1.34
Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. Kidney Int (1984) 1.29
Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl (1997) 1.28
Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis (1987) 1.23
Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther (1991) 1.22
Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int (1990) 1.21
Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. N Engl J Med (1981) 1.21
The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension (1992) 1.20
Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis (1987) 1.19
Survival and rehabilitation of patients on home hemodialysis. Five years' experience. Ann Intern Med (1973) 1.13
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res (1988) 1.13
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int (1988) 1.09
Acute oxalate nephropathy after massive ascorbic acid administration. Arch Intern Med (1985) 1.09
Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest (1987) 1.09
Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients. Am J Kidney Dis (1986) 1.08
Marfan syndrome. Demonstration of abnormal elastin in aorta. J Clin Invest (1982) 1.05
Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1. Am J Pathol (1986) 1.04
Incidence and type of infections occurring in 445 chronic hemodialysis patients. Trans Am Soc Artif Intern Organs (1977) 1.03
Synthesis of soluble elastin by aortic medial cells in culture. Biochem Biophys Res Commun (1974) 1.02
Recent advances in statins and the kidney. Kidney Int Suppl (1999) 1.01
Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol (1995) 0.99
Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J (1988) 0.98
Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology (1985) 0.98
Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol (1987) 0.98
Unilateral Shwartzman reaction: cortical necrosis in one kidney following in vivo perfusion with endotoxin. Kidney Int (1977) 0.98
Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. J Clin Pharmacol (1994) 0.96
Role of hypertension in progressive glomerular immune injury. Hypertension (1985) 0.96
Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med (1985) 0.96
Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. Lab Invest (1985) 0.95
Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol (1985) 0.95
Marfan's syndrome: structural, biochemical, and mechanical studies of the aortic media. J Lab Clin Med (1985) 0.94
Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis (1995) 0.93
Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med (1992) 0.92
Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension (1992) 0.92
Opsonization of Legionella pneumophila in human serum: key roles for specific antibodies and the classical complement pathway. Immunology (1985) 0.91
Anemia, iron storage and ceruloplasmin in copper nutrition in the growing rat. J Nutr (1973) 0.91
Codeine dosage in renal failure. Clin Pharm (1986) 0.90
Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int (2001) 0.90
Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med (1985) 0.90
Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages. Infect Immun (1984) 0.89
Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis (1993) 0.89
Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. Contrib Nephrol (1997) 0.88
Adriamycin-induced chronic proteinuria: a structural and functional study. J Lab Clin Med (1985) 0.88
Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol (1987) 0.88
Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest (1993) 0.87
Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant (1998) 0.87
Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther (1988) 0.87
Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages. Infect Immun (1985) 0.87
Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes. Kidney Int (1998) 0.87
Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun (2000) 0.86
Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition. J Lab Clin Med (1981) 0.86
Cefsulodin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother (1983) 0.86
Hyperlipidemia in the nephrotic syndrome. N Engl J Med (1990) 0.86
Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis (1998) 0.85
Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing. Antimicrob Agents Chemother (1989) 0.85
The central role of nuclear factor-kappa B in mesangial cell activation. Kidney Int Suppl (1999) 0.85
Determinants of glomerular filtration and plasma flow in experimental diabetic rats. J Lab Clin Med (1981) 0.85
Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. Nephron (1979) 0.85
Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant (1996) 0.85
Impaired mesangial clearance of macromolecules in rats with chronic mesangial ferritin-antiferritin immune complex deposition. Lab Invest (1980) 0.85
Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int (2001) 0.85
Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians. Clin Nephrol (1996) 0.84
An evaluation of the physicochemical risk for renal stone disease during pregnancy. Clin Nephrol (2001) 0.84
Lipids and progressive renal disease: the cardio-renal link. Am J Kidney Dis (1999) 0.84
The national epidemic of chronic kidney disease. What we know and what we can do. Postgrad Med (2001) 0.84
Glomerular mesangium: its function and relationship to angiotensin II. Am J Med (1985) 0.83
Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int Suppl (1999) 0.83
Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int (1989) 0.82
Biosynthesis of elastin by an endothelial cell culture. Biochem Biophys Res Commun (1979) 0.82
The assessment of risk factors in 462 patients with acute renal failure. Am J Kidney Dis (1985) 0.81
Intestinal and hepatic cholesterol synthesis in the alloxan diabetic rat. Proc Soc Exp Biol Med (1982) 0.81
The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study. Clin Pharmacol Ther (1991) 0.81
Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease. Antimicrob Agents Chemother (1992) 0.81
Radiation-induced renal disease. A clinicopathologic study. Am J Med (1976) 0.81
Hemodialysis elimination rates and clearance of gentamicin and tobramycin. Antimicrob Agents Chemother (1984) 0.81
Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease. Antimicrob Agents Chemother (1990) 0.81
Cefsulodin pharmacokinetics during hemodialysis. Trans Am Soc Artif Intern Organs (1982) 0.80
Glucose-induced increases in renal hemodynamic function. Possible modulation by renal prostaglandins. Diabetes (1985) 0.80
Elastin in diseases. J Invest Dermatol (1982) 0.80
Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int (1995) 0.80
Lipids in progression of renal disease. Kidney Int Suppl (1997) 0.80
The effects of chronic mesangial immune injury on glomerular function. J Lab Clin Med (1980) 0.80